Apimeds Pharmaceuticals US, Inc. (APUS)

The immediate outlook is severely compromised by a catastrophic 97% collapse from the $17.80 level seen last July to the current $0.72, leaving the stock trading near its absolute lows. This precipitous drop coincides with a 1-for-10 reverse split and a settlement of disputes, signaling deep distress rather than a standard correction. Fundamentally, the company is bleeding cash with negative earnings per share of -$2.72 and no revenue growth history available due to the lack of multi-year price data. There is no dividend to provide income, and the balance sheet appears fragile given the market's verdict of a 99% loss of value in a single year. While the recent price action shows some minor consolidation after the crash, the structural damage to the business model and the extreme dilution risk from the reverse split make this a clear avoid for both short-term traders and long-term investors.